Novartis ended 2020 on a decent note, thanks to a sustained sales recovery momentum and impressive margin progression. While 2021 sales momentum is guided to remain in check, an adequate cushion should surface via incremental targeted cost improvements, thereby supporting the group’s shareholder rewards. Moreover, with various (disruptive) innovations – across new treatment frontiers, in the making, the long-term business potential also seems sorted. Hence, we recommend staying invested.
27 Jan 2021
Profit improvements (potential) overshadow sales moderation (guidance)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Profit improvements (potential) overshadow sales moderation (guidance)
Novartis ended 2020 on a decent note, thanks to a sustained sales recovery momentum and impressive margin progression. While 2021 sales momentum is guided to remain in check, an adequate cushion should surface via incremental targeted cost improvements, thereby supporting the group’s shareholder rewards. Moreover, with various (disruptive) innovations – across new treatment frontiers, in the making, the long-term business potential also seems sorted. Hence, we recommend staying invested.